[{"id":"0206427b-6413-49b4-a589-ddaddbc55f24","acronym":"","url":"https://clinicaltrials.gov/study/NCT00050752","created_at":"2021-01-18T00:05:26.913Z","updated_at":"2025-02-25T13:38:46.395Z","phase":"","brief_title":"Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer","source_id_and_acronym":"NCT00050752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FH","pipe":" | ","alterations":" FH mutation","tags":["FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FH mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 02/24/2003","start_date":" 02/24/2003","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"33d5f034-1f24-4b8e-8660-9bee0a8cde4a","acronym":"BRISK","url":"https://clinicaltrials.gov/study/NCT05904457","created_at":"2023-06-15T17:08:23.101Z","updated_at":"2024-07-02T16:35:45.729Z","phase":"Phase 2","brief_title":"A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer","source_id_and_acronym":"NCT05904457 - BRISK","lead_sponsor":"Asan Medical Center","biomarkers":" FH","pipe":"","alterations":" ","tags":["FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib • Aybintio (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/02/2023","start_date":" 01/02/2023","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-06-14"},{"id":"6e3f90ef-b0d9-4781-a5ea-e47823f7ed76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603365","created_at":"2021-01-19T20:30:55.953Z","updated_at":"2024-07-02T16:35:47.797Z","phase":"Phase 2","brief_title":"Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer","source_id_and_acronym":"NCT04603365","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" FH","pipe":"","alterations":" ","tags":["FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 05/07/2023","primary_completion_date":" 05/07/2023","study_txt":" Completion: 05/07/2023","study_completion_date":" 05/07/2023","last_update_posted":"2023-05-17"},{"id":"ba0b67f1-c5e5-4ec3-a0a5-2e11cd4844d5","acronym":"IUNU-RC","url":"https://clinicaltrials.gov/study/NCT05768464","created_at":"2023-03-14T14:01:50.999Z","updated_at":"2024-07-02T16:35:53.327Z","phase":"Phase 2","brief_title":"Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors","source_id_and_acronym":"NCT05768464 - IUNU-RC","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" SMARCB1 • FH","pipe":"","alterations":" ","tags":["SMARCB1 • FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2023-03-14"}]